Tag Archives: Evaluate

Appointments, News

Evaluate appoints Matthew Wright as Chief Financial Officer

London, UK and Boston, MA – 11 May 2022 – Evaluate, a leading provider of market intelligence and predictive analytics for the pharmaceutical industry, has today announced that it has appointed Matthew Wright as Chief Financial Officer. Wright will work closely with both the Evaluate and Norstella executive and finance teams as the newly merged organisation combines as a $1.6 billion global pharma commercial intelligence provider.

Wright commented: “This is a really exciting time to join the business as it comes together to build a comprehensive data, insight and intelligence solution that will inform and support the industry across the entire drug lifecycle from pipeline to patient.

“I look forward to working with the leadership team to further extend our reach so that we can make an even greater contribution to those that are bringing new drugs to market and help patients gain access to life-saving therapies, faster,” he said.

Wright has over 15 years’ experience as a seasoned executive, providing financial analysis of performance, growth and acquisition opportunities and strategic decision support to senior leadership teams. He joins Evaluate from Informa Intelligence where he was most recently Finance Director for Pharma and Financial. He previously held similar roles at TNT Express and Ascential and brings complementary knowledge of high value B2B subscription business to Evaluate.

Lucy Ralph, CAO of Evaluate, added: “We have ambitious growth plans for the future as a newly merged business. We are determined to build on our success to date by offering an end-to-end view of the pharmaceutical market landscape and I’m confident that Matt will play a central role in helping us to grow as a business.”

News, Research

Evaluate report signals orphan drug market is niche no more

London, UK – 28 April 2022 – Evaluate, the leading provider of market intelligence and predictive analytics for the pharmaceutical industry, has today released the findings of its 2022 Orphan Drug Report.

Evaluate’s data shows that the orphan drug market is growing more than twice as fast as the non-orphan pharmaceuticals market, with 2021-2026 CAGR topping 12%. By 2026 orphan drug sales will account for 20% of all prescription drug sales and almost a third of the global drug pipeline’s value. Each of the top ten orphan blockbusters in 2026 will be worth between $3 billion and $13 billion and look set to out-size mass market drugs.

Big pharma’s increasing reliance on orphan drugs for sales is anticipated to continue, with nine of the top-ten best-selling orphan drugs in 2026 expected to be marketed or co-marketed by big pharma. Over a fifth of sales at eight big pharma will also be from orphans. Four blood cancer drugs will account for about half of the $65 billion combined sales from 2026’s top ten orphans.

Paul Verdin, VP Consulting and Analytics at Evaluate said: “The orphan drug sector continues to experience rapid growth. Over half of the FDA’s approvals in 2021 were assigned to orphan drugs intended to treat rare diseases, a development that signals that orphan drugs should no longer be regarded as niche products.

“Orphans’ strong growth is leading to crowding in some corners of the market, but many of the estimated 7,000 rare diseases remain under-served, so the opportunity for further investment and R&D is high. As other diseases are better understood and sliced into narrower sub-categories, they are more likely to meet the criteria for a rare condition,” he added.

The report notes that the rise of orphan drug blockbusters may drive calls to reform the 40 year old US Orphan Drug Act and the European Union’s 1999 Orphan Regulation to temper prices. While this may result in changes to reimbursement, especially in Europe’s biggest market, Germany, the orphan drug market shows no sign of losing momentum.

The pharma R&D pipeline is currently packed with next-generation CAR-T cell therapies, gene therapies, targeted cancer drugs and other new modalities – many with orphan designations. The net present value of forecast 2026 sales of the top ten pipeline orphan drugs is more than $42 billion.

Read the 2022 Evaluate Orphan Drug Report in full here: https://www.evaluate.com/thought-leadership/pharma/orphan-drug-2022-report?utm_source=PR&utm_medium=PR&utm_campaign=Orphan_Drug_2022

Data & Analytics, News

Evaluate announces global strategic collaboration with Treehill Partners

London, UK and New York, USA – 21 April 2022 – Evaluate and Treehill Partners today announced that they have entered into a global strategic collaboration to combine Evaluate’s industry leading data analytics and strategic consulting with Treehill’s world class transaction advisory and execution services in healthcare.

Both organisations have decades of experience serving customers globally and are joining forces to provide their combined client base with a richer suite of proprietary services and tools that now span strategic consultancy on market and product evaluations to transaction advisory and execution. This collaboration is a natural strategic fit for both groups whose focus is on fact-based advice, directed by real-world experience. It addresses the increasing demand for strategic and transaction support from Evaluate’s existing customers.

Cem Baydar, Chief Consulting Officer at Evaluate, commented: “This alliance demonstrates our strong commitment to our clients, providing them with enhanced services in areas where we are seeing increasing demand, notably transactions related advisory. The combination of our proprietary data analytics platform and our strategic consulting services with the transaction advisory and execution capabilities of Treehill will bring tremendous value to our clients. I am delighted that we will be providing them with a seamless and integrated team that can serve corporate development needs more holistically.”

Evaluate provides the most comprehensive data and consensus forecasting the pharmaceutical and life sciences industry. “Together we will leverage Evaluate’s data and our consulting services in asset and portfolio strategy, commercial assessment and due diligence, to inform a highly specialised expert approach that we will jointly take to situational assessment, strategic leadership consulting, and transaction advisory,” Baydar added.

Ali Pashazadeh, Partner and Co-Founder at Treehill Partners, said: “At Treehill Partners, our advisory services are based on providing our clients with the best advice at the right time, and we have found in Evaluate a partner that shares the same philosophy. This collaboration represents a unique value proposition in the marketplace as it brings our transaction perspective and execution capability into Evaluate’s strategic healthcare consulting practice, providing our shared clients with a uniquely differentiated solution to their situational strategic and transaction needs.”